silodosin

01/01/2013 - "Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies."
06/01/2009 - "Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies."
05/07/2011 - "In men aged >50 years with benign prostatic hyperplasia (BPH), silodosin 8 mg once daily, compared with placebo, was associated with a significantly more rapid and effective improvement in the total International Prostate Symptom Score (IPSS) and the storage and voiding IPSS subscores in three 12-week, phase III trials conducted in Europe and the US. "
01/01/2011 - "The uroselective α-blocker silodosin significantly improved International Prostate Symptom Score (IPSS) in two 12-week, double-blind (DB), placebo-controlled Phase III studies in men aged ≥ 50 years with symptoms of benign prostatic hyperplasia (BPH) and maintained symptom improvement during a 9-month open-label (OL) extension. "
01/01/2010 - "Pooled results from 2 randomized, placebo-controlled, US phase III studies (NCT00224107, NCT00224120) showed that silodosin, a uroselective α-blocker, significantly improved International Prostate Symptom Scores (IPSS) in men with symptomatic benign prostatic hyperplasia (BPH). "

12/01/2012 - "This meta-analysis proves silodosin to be an effective and safe treatment for the relief of lower urinary tract symptom associated with BPH. "
01/01/2021 - "We performed a post hoc analysis of data from phase 3 and 4 studies to evaluate the efficacy of silodosin 8mg in patients with severe lower urinary tract symptoms (LUTS) related to benign prostatic obstruction (BPO). "
06/01/2021 - "Improvement in Near Vision Following Silodosin Treatment in Patients With Lower Urinary Tract Symptoms."
01/01/2014 - "Our findings showed the Core Lower Urinary Tract Symptom Score, both its total score and each subscore, is able to show the efficacy of silodosin, similar to other questionnaires. "
01/01/2014 - "The efficacy of silodosin for treating lower urinary tract symptoms was validated according to the total scores of all four questionnaires weighted equally (P < 0.05). "

10/01/2014 - "Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies."
01/01/2022 - "Literature reveals that silodosin is beneficial in improving nocturia events related to LUTS/BPH. "
01/01/2010 - "Compared with placebo, silodosin significantly improved nocturia within 1 week (silodosin, -0.5 ± 1.07 versus placebo, -0.3 ± 1.05; P = 0.009) and all other symptoms within 3 to 4 days (P < 0.01). "
01/01/2010 - "Decrease in score from baseline (mean ± standard deviation) to last observation was significantly greater with silodosin than with placebo for all symptoms (P < 0.005); symptom improvement with silodosin (versus placebo) was greatest for weak stream (silodosin, -1.1 ± 1.4 versus placebo, -0.5 ± 1.2; P < 0.0001) and smallest for nocturia (silodosin, -0.6 ± 1.1 versus placebo, -0.4 ± 1.2; P = 0.0037). "
01/01/2014 - "Silodosin is effective in reducing BPH/LUTS, including nocturia and shows little cardiovascular adverse events. "

10/01/2018 - "Silodosin administration significantly improved the International Prostate Symptom Score and Overactive Bladder Symptom Score. "
03/01/2015 - "In contrast, the efficacy of treatment with silodosin 4 mg twice daily was greater than that of 4 mg once daily, based on both the quality of life index and the Overactive Bladder Symptom Score total score. "
03/01/2019 - "Patients completed questionnaires, including the International Prostate Symptom Score (IPSS), quality of life (QOL) score and Overactive Bladder Symptom Score (OABSS) at baseline (time of switching) and after 3 months of treatment with silodosin. "
03/01/2015 - "In contrast, silodosin 4 mg twice daily is more effective on storage symptoms evaluated by the Overactive Bladder Symptom Score than silodosin 4 mg once daily."
10/30/2021 - "The aim of our study will be to evaluate the effect of combining pelvic floor muscle training (PFMT) with the urgency-suppression technique and silodosin in comparison with silodosin alone in men with Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB) after 12 weeks of treatment. "

01/01/2017 - "The magnitude of bladder outlet obstruction improvement in patients receiving silodosin is higher if compared to other ABs. "
12/01/2014 - "The pressure flow studies demonstrated that silodosin had significantly enlarged the bladder capacity when the first non-voiding contraction was seen at 3 and 12 months (3M: 127.1 ± 74.8 vs. 118.2 ± 83.9 mL, p = 0.001; 12M: 123.7 ± 79.3 vs. 100.3 ± 73.4 mL, p = 0.01); however, there were no improvements in the bladder outlet obstruction index (BOOI) or urinary flow. "
03/01/2018 - "A significant decrease in bladder outlet obstruction index was observed with silodosin reception (Urorec®) 8 mg once daily (-28.8 [95% CI: -28.2, -29.5] or -44.5% [95% CI: -43.4%, - 45.5%] (p <0.001)), a decrease in IPSS scores after 30, 60 and 120 days from initiation of treatment (-6.3 [95% CI: -5.9, -6.7], -6.5 [95% CI: -6.1, - 6.9], -6.8 [95% CI: -6.4, -7.2] respectively (p <0.001)), an increase in Qmax after 7, 14, 30, 60 and 120 days from initiation of treatment (+1.1 mL/s [95% CI: 1.0 mL/s, 1.2 mL/s], +1.6 mL/s [95% CI: 1.5 mL/s, 1.7 mL/s], +2.4 mL/s [95% CI: 2.3 mL/s, 2.5 mL/s], +2.5 mL/s [95% CI: 2.4 mL/s, 2.6 mL/s], +2.5 mL/s [95% CI: 2.4 mL/s, 2.7 mL/s] respectively (p <0.001)). "
01/01/2018 - "We investigated the effects of silodosin, an α1A-adrenoceptor (AR) antagonist, on bladder function, especially on non-voiding contractions (NVCs), in a male rat model of bladder outlet obstruction (BOO) by evaluating cystometry (CMG) findings and bladder mechanosensitive single-unit afferent activities (SAAs), related with microcontractions, which may be similar with NVCs and to be of myogenic origin, in the rat model. "
01/01/2018 - "Inhibitory effects of silodosin on the bladder mechanosensitive afferent activities and their relation with bladder myogenic contractions in male rats with bladder outlet obstruction."